Solana Company (HSDT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Solana Company (HSDT) Healthcare & Pipeline Overview

Solana Co. (HSDT) is a neurotech company specializing in non-invasive neuromodulation devices. They develop and license technologies aimed at enhancing neurological wellness and reducing symptoms of neurological conditions. Their investigational portable neuromodulation stimulator is designed to improve the effectiveness of physical exercises for patients with neurological impairments.

What Is the Investment Thesis for HSDT?

Solana Co. presents a focused investment opportunity within the neurotech sector, centered on its investigational portable neuromodulation stimulator. The company's high gross margin of 91.7% suggests potential for strong profitability upon successful commercialization. A key value driver is the potential market for non-invasive neurological treatments, addressing conditions like traumatic brain injury. Upcoming clinical trial results for the neuromodulation stimulator represent a significant catalyst. However, the company's negative profit margin of -679.6% highlights the risks associated with early-stage development and the need for substantial capital investment. The company's relatively small market capitalization of $126M also indicates higher volatility and sensitivity to market fluctuations. Successful navigation of regulatory approvals and demonstration of clinical efficacy are critical for realizing the company's potential.

Based on FMP financials and quantitative analysis

HSDT Key Highlights

Gross Margin of 91.7% indicates strong potential profitability upon successful commercialization of its neuromodulation technology.

• Market Cap of $126M reflects its status as a small-cap company with potential for high growth but also higher volatility.
• Profit Margin of -679.6% highlights the company's current reliance on investment and the absence of significant revenue streams.
• Beta of 0.91 suggests that the stock's volatility is slightly less than the overall market.
• Focus on non-invasive neuromodulation aligns with growing demand for less invasive medical treatments.

Who Are HSDT's Competitors?

HSDT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are HSDT's Key Strengths?

Innovative non-invasive neuromodulation technology.

• High gross margin potential.
• Focus on a growing market for neurological wellness.
• Experienced management team.

What Are HSDT's Weaknesses?

Negative profit margin.

• Small market capitalization.
• Reliance on a single product in development.
• Limited commercialization experience.

What Could Drive HSDT Stock Higher?

Clinical trial results for the investigational portable neuromodulation stimulator.

• Regulatory approval process for the neuromodulation device.
• Potential partnerships with rehabilitation centers and clinics.
• Securing additional funding for research and development.

What Are the Key Risks for HSDT?

Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

• Failure to obtain regulatory approvals.
• Competition from established medical device companies.
• Technological obsolescence.
• Limited access to capital.
• Negative profit margin and reliance on external funding.

What Are the Growth Opportunities for HSDT?

• Expansion into New Neurological Indications: Solana Co. can leverage its neuromodulation platform to target additional neurological conditions beyond traumatic brain injury, such as stroke rehabilitation, Parkinson's disease, and chronic pain management. Each of these indications represents a significant market opportunity, with the global market for Parkinson's disease treatment projected to reach $5.6 billion by 2028. Successful expansion into these areas would diversify the company's revenue streams and reduce its reliance on a single product or indication. This expansion is contingent on further research and clinical trials to validate the efficacy of its technology for these new applications, with a timeline of 3-5 years.
• Strategic Partnerships with Rehabilitation Centers: Collaborating with rehabilitation centers and clinics would provide Solana Co. with direct access to patients and clinicians, facilitating adoption of its neuromodulation technology. These partnerships could involve integrating the company's device into existing rehabilitation programs and providing training to healthcare professionals. The market for rehabilitation services is substantial, with the global rehabilitation equipment market expected to reach $18.8 billion by 2027. These partnerships would also generate valuable real-world data on the effectiveness of the technology, supporting further development and marketing efforts. The timeline for establishing these partnerships is estimated at 1-2 years.
• Licensing and OEM Agreements: Solana Co. can pursue licensing agreements with larger medical device companies or original equipment manufacturers (OEMs) to expand the reach of its technology. This would allow the company to leverage the established sales and distribution networks of its partners, accelerating market penetration. The medical device OEM market is a multi-billion dollar industry, offering significant opportunities for collaboration. These agreements could generate upfront licensing fees and ongoing royalties, providing a stable revenue stream. The timeline for securing these agreements is estimated at 2-3 years.
• Development of Telehealth Applications: Integrating its neuromodulation technology with telehealth platforms would enable remote monitoring and treatment of patients, expanding access to care and reducing the need for in-person visits. The telehealth market is experiencing rapid growth, driven by the increasing adoption of remote healthcare solutions. The global telehealth market is projected to reach $55.6 billion by 2027. This integration would also allow for personalized treatment plans based on real-time data, improving patient outcomes. The timeline for developing and implementing telehealth applications is estimated at 2-3 years.
• Securing Regulatory Approvals and Reimbursement: Obtaining regulatory approvals from agencies like the FDA and securing favorable reimbursement policies from insurance providers are critical for the commercial success of Solana Co.'s technology. These approvals would validate the safety and efficacy of the device and enable widespread adoption by healthcare providers. The process of securing regulatory approvals and reimbursement can be lengthy and costly, but it is essential for establishing market access and generating sustainable revenue. The timeline for achieving these milestones is estimated at 2-4 years.

What Are HSDT's Competitive Advantages?

• Proprietary neuromodulation technology.
• Focus on non-invasive treatment methods.
• Potential for strong intellectual property protection through patents.
• Early mover advantage in the emerging neurotech market.

What Does HSDT Do?

Solana Co., founded on March 13, 2014, is a neurotech company operating within the medical device industry. Headquartered in Newtown, PA, the company focuses on developing, licensing, and acquiring non-invasive platform technologies designed to enhance neurological wellness. Solana Co.'s core mission is to amplify the brain’s natural ability to heal itself and alleviate symptoms associated with neurological diseases and trauma. Their primary product under development is an investigational portable neuromodulation stimulator. This device delivers neurostimulation via the tongue and is intended to enhance the effectiveness of physical exercises for individuals experiencing neurological symptoms resulting from conditions like mild-to-moderate traumatic brain injury. The company's approach centers on non-invasive methods, aiming to provide accessible and effective solutions for neurological rehabilitation and wellness. Solana Co. operates with a relatively small team of 21 employees, indicating a focused and agile approach to product development and market entry. The company's strategy involves both internal development and external acquisition of promising technologies in the neurotech space, allowing them to build a comprehensive portfolio of solutions for neurological wellness.

What Products and Services Does HSDT Offer?

• Develops non-invasive platform technologies for neurological wellness.
• Focuses on amplifying the brain’s ability to heal itself.
• Reduces symptoms of neurological disease or trauma.
• Creates investigational portable neuromodulation stimulators.
• Delivers neurostimulation via the tongue.
• Enhances the effectiveness of physical exercises for people with neurological symptoms.

How Does HSDT Make Money?

• Develops and licenses non-invasive neuromodulation technologies.
• Acquires promising technologies in the neurotech space.
• Generates revenue through potential future sales of neuromodulation devices.
• May generate revenue through licensing agreements with other medical device companies.

What Industry Does HSDT Operate In?

Solana Co. operates in the rapidly evolving neurotech sector, which is experiencing increased investment and innovation. The market for neuromodulation devices is driven by the rising prevalence of neurological disorders and the demand for non-pharmacological interventions. The competitive landscape includes established medical device companies and emerging startups focused on brain stimulation and neurorehabilitation. Solana Co.'s focus on non-invasive, portable neuromodulation positions it to capitalize on the trend towards personalized and accessible healthcare solutions. The company's success will depend on its ability to demonstrate clinical efficacy and secure regulatory approvals in a competitive market.

Who Are HSDT's Key Customers?

• Individuals with neurological symptoms from disease or trauma.
• Patients with mild-to-moderate traumatic brain injury.
• Rehabilitation centers and clinics.
• Healthcare providers specializing in neurological care.

Solana Company (HSDT) Valuation Context

Valued at $126M, HSDT is classified as a micro-cap stock. Relative to its peer group, HSDT's quantitative score of 20/100 is below the peer average of 54/100.

HSDT Revenue & Earnings Trend

In Q2 FY2026, HSDT generated $2.5M in top-line revenue, marking a sequential decrease of 30.2%. The company recorded a net loss of $30.3M, with diluted EPS of $-0.39. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, HSDT averaged $-32.49 in diluted EPS.

Company Profile

Solana Company operates in the Asset Management industry within the Financial Services sector. It is headquartered in Newtown, US. The company is led by CEO Dane Carl Andreeff. HSDT has traded publicly since 2014.

Key Financial Metrics

Return on assets is -68.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -18.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.90 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -108.1%, the inverse of the P/E and a quick read on earnings relative to price.

Solana Company's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.39 places it in the grey zone, a middle ground that warrants monitoring.

Solana Company has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 9063.0% below estimates on average.

Over the past six months, Solana Company insiders filed 27 SEC Form 4 transactions — 5 sales and 22 purchases. On net that is roughly 1.7M shares disposed (about $2.5M), a signal worth weighing alongside the fundamentals.

HSDT Financials

HSDT Latest News

HSDT Analyst Consensus

HSDT MoonshotScore

Latest Solana Company Analysis

What Investors Ask About Solana Company (HSDT) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources